ÁøÀº¼± ¸íÀÇ

±¹³» ¼ºÀÎ ºÎÁ¤¸Æ ºÐ¾ß ¿©¼º Àü¹®ÀÇ 1È£ÀÇ ºÎÁ¤¸Æ ±ÇÀ§ÀÚ

ÁøÀº¼± ¸íÀÇ

  • ¼Ò ¼Ó
    °­µ¿°æÈñ´ëÇб³º´¿ø
  • Áø·á°ú
    ½ÉÇ÷°ü³»°ú
  • Àü¹®ºÐ¾ß
    ½ÉÀå³»°ú, ºÎÁ¤¸Æ

½ÉÀåÇ÷°ü³»°ú ÀÇ»ç·Î ºÎÁ¤¸ÆÀ» Àü¹®À¸·Î Áø·áÇϰí ÀÖ´Ù. ±¹³» ¼ºÀÎ ºÎÁ¤¸Æ ¿©¼º Àü¹®ÀÇ 1È£·Î 20³âÀÌ ³Ñ´Â dzºÎÇÑ ÀÓ»ó°æÇèÀ» ¹ÙÅÁÀ¸·Î ºÎÁ¤¸Æ ȯÀÚµéÀÇ ½Å·Ú¸¦ ¹Þ°í ÀÖ´Ù. °æÈñ´ë Àǰú´ëÇÐÀ» Á¹¾÷Çϰí, µ¿´ëÇб³ ¼®¹Ú»ç¸¦ Áö³Â´Ù. Ç×»ó ȯÀÚ¸¦ ¸¸³¯ ¶§, '³» ¸öÀ̶ó¸é' À̶ó´Â »ý°¢À¸·Î ÇöÀç °¡Àå ¾ÈÀüÇϰí È®°íÇÑ ±Ù°Å¸¦ °¡Áø Ä¡·á¸¦ ÇÏ¿© ȯÀÚ¿ÍÀÇ ±»Àº ½Å·Ú °ü°è°¡ Çü¼ºµÇ¾î ÀÖ´Ù. 16³âÀÇ ºÎÁ¤¸Æ ½Ã¼ú °æÇèÀ¸·Î À¯¼öÀÇ ºò¼¾ÅÍ¿Í °ßÁ־ ºÎÁ·ÇÏÁö ¾ÊÀ» ÈǸ¢ÇÑ ½Ç·Â°ú ÀںνÉÀ» °¡Áø µ¿·áµé°úÀÇ Çù·ÂÀ¸·Î ÀÛÁö¸¸ °­ÇÑ ½ÉÀåÇ÷°ü³»°ú¸¦ À̲ø°í ÀÖ´Ù.

¸íÀÇÇÁ·ÎÇÊ ¸íÀÇ ÇÁ·ÎÇÊ

ÇзÂ

Educational Background
  • °æÈñ´ë ÀÇ´ë Çлç
  • °æÈñ´ë ÀÇ´ë ¼®»ç
  • °æÈñ´ë ÀÇ´ë ¹Ú»ç

ÁÖ¿ä°æ·Â

Work Experience
  • úÞ) °­µ¿°æÈñ´ëÇб³º´¿ø ½ÉÀåÇ÷°ü³»°ú °úÀå
  • °­µ¿°æÈñ´ëÇб³º´¿ø ½ÉÀåÇ÷°ü¼¾ÅÍ ½ÉÀåÇ÷°ü³»°ú ±³¼ö
  • °æÈñ´ëÇб³ Àǰú´ëÇÐ ÀÓ»ó½Ç½À±³À°½ÇÀå
  • °æÈñ´ëÇб³ Àǰú´ëÇÐ ÀÓ»ó½Ç½À±³À°½ÇÀå °â ÀÓ»ó½Ç½À¼ö±â¼¾ÅÍÀå
  • ´ëÇѺÎÁ¤¸ÆÇÐȸ ÁßÀç½Ã¼ú Àü¹®ÀÇ
  • °­µ¿°æÈñ´ëÇб³º´¿ø QPS½ÇÀå
  • °­µ¿°æÈñ´ëÇб³º´¿ø ÀûÁ¤°ü¸®½Ç ºÎ½ÇÀå
  • °Ç°­º¸Çè½É»çÆò°¡¿ø ÀÚ¹®À§¿ø
  • Stanford University ¹æ¹®±³¼ö
  • ¼­¿ï¾Æ»êº´¿ø ½ÉÀå³»°ú ÀÓ»ó°­»ç ¹× ÃËŹÀÇ
  • °æÈñÀÇ·á¿ø ¼ö·ÃÀÇ ¹× Àü°øÀÇ

ÇÐȸȰµ¿

Academic activities
  • 2024 ~ ÇöÀç´ëÇѺÎÁ¤¸ÆÇÐȸ ±³À°ÀÌ»ç
  • 2022 ~ 2023´ëÇѺÎÁ¤¸ÆÇÐȸ Áø·áÁöħÀÌ»ç, ÇмúÀ§¿ø
  • 2022 ~ 2023¾Æ½Ã¾Æ-ÅÂÆò¾ç ºÎÁ¤¸ÆÇÐȸ (APHRS) ¿©¼ººÐ°úÀå
  • 2020 ~ 2024´ëÇѽÉÀåÇÐȸ ÀÇ·áÁ¤º¸À§¿ø, Áø·áÁöħÀ§¿ø
  • 2022 ~ 2023Çѱ¹ ÁöÁúµ¿¸Æ°æÈ­ÇÐȸ È«º¸À§¿øÈ¸ °£»ç
  • 2022 ~ 2023´ëÇÑÀÇÇаú ÀÏÂ÷Áø·áÀǸ¦ À§ÇÑ ½É¹æ¼¼µ¿ Ä¡·áÁöħ Á¦Á¤À§¿øÈ¸ °£»ç
Àú¼­ ¾ÆÀÌÄÜ

ÁýÇÊÀú¼­

ÃÑ 2°Ç
Á¦ ¸ñ ºÎÁ¤¸Æ Arrhythmia
ÃâÆÇ»ç ±ºÀÚÃâÆÇ»ç ¹ßÇàÀÏ 2012³â
Á¦ ¸ñ ÀÏÂ÷Áø·á¿ë ±Ù°Å±â¹Ý ½É¹æ¼¼µ¿ ÀÓ»óÁø·áÁöħ
ÃâÆÇ»ç ´ëÇÑÀÇÇÐȸ/Áúº´°ü¸®Ã» ¹ßÇàÀÏ 2023³â 02¿ù 28ÀÏ
¿¬±¸ ¾ÆÀÌÄÜ

ÁÖ¿ä³í¹®

ÃÑ 7°Ç
Á¦ ¸ñ Edoxaban Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Artery Disease
¹ßÇ¥³âµµ 2024 ¹ßÇ¥Áö NEJM(New England Journal of Medicine)
Á¦ ¸ñ Impact of Trimetazidine on the Incident Heart Failure After Coronary Artery Revascularization
¹ßÇ¥³âµµ 2023 ¹ßÇ¥Áö Journal of cardiovascular pharmacology
Á¦ ¸ñ Dyslipidemia Fact Sheet in South Korea, 2022
¹ßÇ¥³âµµ 2023 ¹ßÇ¥Áö Diabetes and Metabolism Journal
Á¦ ¸ñ Net clinical benefit of oral anticoagulants in Korean atrial fibrillation patients with low to intermediate stroke risk: A report from the Clinical Survey on Stroke Prevention in patients with Atrial Fibrillation (CS-SPAF)
¹ßÇ¥³âµµ 2023 ¹ßÇ¥Áö JOURNAL OF ARRHYTHMIA
Á¦ ¸ñ Public Awareness of Dyslipidemia among the Korean Population: A Survey Study
¹ßÇ¥³âµµ 2023 ¹ßÇ¥Áö Journal of lipid and atherosclerosis
Á¦ ¸ñ Adherence and clinical outcomes for twice-daily versus once-daily dosing of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: Is dosing frequency important
¹ßÇ¥³âµµ 2023 ¹ßÇ¥Áö PLoS ONE
Á¦ ¸ñ Bone formation effect of highly concentrated tricalcium phosphate biocomposite screws in a rabbit osteoporosis model
¹ßÇ¥³âµµ 2022 ¹ßÇ¥Áö JOURNAL OF ORTHOPAEDIC RESEARCH

¸íÀÇqna ¸íÀÇ QnA

Q °¡Àå °ü½É ÀÖ´Â ºÐ¾ß¿Í ¾÷ÀûÀÌ ÀÖ´Ù¸é ¾Ë·ÁÁÖ¼¼¿ä

°ü½É ÀÖ´Â ºÐ¾ß´Â ÇöÀç °¡Àå ¸¹Àº °ü½ÉÀ» ¹Þ°í ÀÖ´Â, ³ú°æ»öÁõÀÇ ¿øÀÎÀÌ µÇ´Â ½É¹æ¼¼µ¿°ú, ¸Å¿ì ÈçÇÑ ºÎÁ¤¸ÆÀÌÁö¸¸ ±Ø¼Ò¼öÀÇ È¯ÀÚ¿¡¼­ ±Þ»ç¸¦ ÀÏÀ¸Å³ ¼ö ÀÖ´Â ½É½ÇÁ¶±â¼öÃà ºÎÁ¤¸Æ¿¡ °ü½ÉÀÌ ÀÖ½À´Ï´Ù.
±× ¿Ü¿¡µµ ºÎÁ¤¸Æ ÁúȯÀº ¸Å¿ì ´Ù¾çÇϰí À§ÇèÇÑ ÁúȯµéÀÌ ¸¹¾Æ¼­ Áß¿äÇÏÁö ¾ÊÀº °ÍÀº ¾ø½À´Ï´Ù.
ÀÌ·¯ÇÑ Á¡ÀÌ, '³» Áö½Ä°ú ¼ÕÀ¸·Î Á×À» ¼öµµ ÀÖ´Â »ç¶÷À» »ì·Á³»´Â »ç¶÷ÀÌ µÇ°íÀÚ' Çß´ø ÀúÀÇ ÀÇÁö¿Í ¸Å¿ì Àß ºÎÇÕÇÏ¿© ½ÉÀåÁúȯ ȯÀÚ¸¦ Ä¡·áÇÏ¸ç »ì¾Æ°¡´Â ¸ÅÀϸÅÀÏÀÌ °¨»çÇϰí Áñ°Å¿î ¸¶À½À̸ç, Á¦°Ô Ä¡·á¸¦ ¹ÞÀº ¼ö¸¹Àº ȯÀÚ¿Í Á¦°¡ °¡¸£Ä£ ¼ö¸¹Àº Á¦ÀÚµéÀÌ ÀúÀÇ °¡Àå ¼ÒÁßÇÑ ¾÷ÀûÀÔ´Ï´Ù.

Q ȯÀÚ Áø·á¿¡ ÀÖ¾î °¡Àå Áß¿äÇÏ°Ô »ý°¢ÇÏ´Â °¡Ä¡´Â?

¸ðµç ȯÀÚ´Â '³» ¸öÀ̶ó »ý°¢Çϰí Ä¡·á'ÇÑ´Ù.
ÀÇÇÐÁö½ÄÀ» ¸íÈ®ÇÏ°Ô ½ÀµæÇϰí, °¡Àå ¾÷µ¥ÀÌÆ® µÇ¾î ÀÖ¾î¾ß ÇÏ¸ç ±Ù°Å°¡ ºÎÁ·ÇÑ Ä¡·á¸¦ Àý´ë °úµµÇÏ°Ô Àû¿ëÇÏÁö ¾Ê´Â´Ù. ½Ã¼úÀ» ÇÏ´Â ÀÇ»ç·Î¼­ ³» ½Ã¼ú¿¡ ÀڽۨÀ» °¡Áöµµ·Ï ²÷ÀÓ¾øÀÌ ÀÍÈ÷°í ¿¬¸¶ÇÑ´Ù.
Àú´Â '³ª ½º½º·Î°¡ ºÎÁ¤¸ÆÀÌ »ý±ä´Ù¸é ³»°¡ ½Ã¼ú¹Þ°í ½ÍÀº ÀÇ»ç'¶ó°í ÀÚºÎÇϰí ÀÖ½À´Ï´Ù.

Q ȯÀڵ鿡°Ô ÀüÇÏ°í ½ÍÀº ¸»¾¸

Àǰú´ëÇÐÀ» Á¹¾÷Çϸ鼭 µç »ý°¢Àº, 'ÀÇÇÐÀ» ¾È´Ù´Â °Í ¸¸À¸·Î »î¿¡ À־ÀÇ ºÒ¾ÈÀÌ ´ëºÎºÐ ÇØ¼ÒµÇ¾î »î¿¡ ÀڽۨÀÌ »ý±ä´Ù' ¿´½À´Ï´Ù.
»ç¶÷ÀÇ ¸ö°ú Áúº´Àº, Àß ¾Ë°í Ä¡·á¸¸ ÇÏ¸é µÇ´Âµ¥ Àß ¸ð¸£±â ¶§¹®¿¡ ¹«¼·°í ºÒ¾ÈÇÑ °ÍÀÔ´Ï´Ù.
ƯÈ÷ ºÎÁ¤¸Æ Áõ»óÀº °ð Á×À» °Í °°Àº ºÒ¾ÈÀ» ÀÏÀ¸Å°±âµµ ÇϹǷΠ¸¹Àº ȯÀںеéÀÌ º´¿ø¿¡ ¿À±âº¸´Ù °ÆÁ¤¿¡ È۽ο© °è½Ã´Â °æ¿ì°¡ ¸¹Àºµ¥, °ÆÁ¤À» ¸¹ÀÌ ÇÏ¸é ½ºÆ®·¹½º·Î ÀÛ¿ëÇØ ¿ÀÈ÷·Á ºÎÁ¤¸ÆÀÌ ¾ÇÈ­µÇ±âµµ ÇÕ´Ï´Ù.
°ÆÁ¤À» ¸ØÃ߽ðí Àü¹®°¡¸¦ ¸¸³ª Áø·á¸¦ º¸½Ã±â ¹Ù¶ø´Ï´Ù.

¸íÀÇqna ¸íÀÇ ¼Ò¼Óº´¿ø

°­µ¿°æÈñ´ëÇб³º´¿ø

Á¾ÇÕº´¿ø
ÀüÈ­ ¾ÆÀÌÄÜ ´ëÇ¥¹øÈ£
1577-5800
À¥»çÀÌÆ® ¾ÆÀÌÄÜȨÆäÀÌÁö

ÁÖ¿ä½Ã¼³

ÀÀ±Þ½Ç ÀÀ±Þ½Ç
Ŭ¸®´Ð Ŭ¸®´Ð
Á¾ÇÕ°ËÁø¼¾ÅÍ Á¾ÇÕ°ËÁø¼¾ÅÍ
¾Ï¼¾ÅÍ ¾Ï¼¾ÅÍ
ÁÖÂ÷½Ã¼³ ÁÖÂ÷½Ã¼³

°­µ¿°æÈñ´ëÇб³º´¿øÀº Àǰú, ÇÑÀǰú, Ä¡°ú´ëÇÐÀ» ¸ðµÎ º¸À¯ÇÑ º´¿øÀ¸·Î, 3°³ ´ëÇк´¿øÀÇ ¼öÁØ ³ôÀº ÀÇ·á¼­ºñ½º¸¦ ÇÑ ¹ø¿¡ ¹ÞÀ» ¼ö ÀÖ´Ù. ¿¬¸éÀû 24,000¿© Æò º»°ü Áö»ó 14Ãþ, º°°ü Áö»ó 4ÃþÀÇ 800º´»óÀ» °®Ãè´Ù. ³úÁúȯ¡¤°üÀý¡¤Ã´Ãß µî Áúȯ Áß½ÉÀ¸·Î ƯȭµÈ ÇùÁø ÀÇ·á
¼­ºñ½º¸¦ Á¦°øÇÏ´Â ÀÇ¡¤ÇÑ ÇùÁø¼¾ÅÍ, ȯÀÚ ¼¼°è ÃÖ°í ¼öÁØÀÇ Áø·á½Ã½ºÅÛÀ» °®Ãá Àǰú
´ëÇк´¿ø, ÇÑÀÇÇÐÀ» ¼±µµÇÏ´Â ÇÑ¹æ ºê·£µåÆÄÀ§ 1À§ ÇÑÀǰú´ëÇк´¿ø¿Í Àü¹®¼º°ú ÆíÀǼºÀ» °®Ãá ȯÀÚ¸¸Á· º´¿øÀÎ Ä¡°ú´ëÇк´¿øÀÌ ÃÖ»óÀÇ ÀÇ·á¼­ºñ½º¸¦ Á¦°øÇϰí ÀÖ´Ù.

°­µ¿°æÈñ´ëÇб³º´¿ø À̹ÌÁö

¼­¿ïƯº°½Ã °­µ¿±¸ µ¿³²·Î 892

Ȩ
³»°¡ ¾Ë°íÀÖ´Â ¸íÀǸ¦ ÃßÃµÇØÁÖ¼¼¿ä